ASCO24 Day 4 Highlights by The Oncology Brothers

• The Oncology Brothers shared on X:

“ASCO24 Day 4 Highlights:

1. ICTAN: Adjuvant anti-EGFR duration in NSCLC

2. EV302: Ev plus Pembro HRQoL update in bladder cancer .

3. CM901 Update in bladder cancer

4. ABRAVE in TNBC

1. ICTAN:

• Phase III, n=251, adj icotinib for 6 or 12 months vs Obs in EGFR resected NSCLC
• 5 year OS: 74% and 74.5% vs. 65.1%
• Stage II 5 year DFS: 55.9% and 56.9% vs. 29.3%
• Stage III 5 year DFS: 45.1% and 47.5% vs. 21.9%
• What’s the right duration for Osi?

2. EV302:

• Enfortumab plus Pembro was approved in Dec 2023 for 1L mUC. Updated HRQoL
• Improvement in all functioning domains with EV 302
• Improved pain and QoL with EV302

3. CM901:

• Chemo plus Nivo was approved in March 2024 for 1L mUC. Update on LN only disease
• ~20% of the patients in this category
• 63% with CR and 18.5% with PR
• mOS: 46.3 months vs 24.9 months (HR: 0.58)

4. ABRAVE:

• Phase III, Adj Avelumab in TNBC after NACT
• Did not meet PFS end point but met OS secondary endpoint.
• 3 year OS 84.8% with Avelumab vs. 76.3% (HR 0.66)
• KN522 as SoC, how does this fit in?
• Importantly, who can we forego IO in adj (if pCR)?”

Source: Oncology Brothers/X